T-cell-specific adapter protein (TSAd) involved in the negative control of T-cell activation is encoded by the SH2D2A gene. Our recent studies indicate that homozygosity for short (ie GA 13 and GA 16 ) alleles of the SH2D2A gene promoter is associated with development of multiple sclerosis. To study whether the same SH2D2A promoter polymorphism also contributes to the genetic susceptibility to develop juvenile rheumatoid arthritis (JRA), we examined 210 JRA patients and 558 healthy unrelated controls from Norway. The frequency of the short allele GA 13 was increased among the JRA patients compared to control (0.098 vs 0.05; P n ¼ 8 ¼ 0.042). There was a significant increased frequency of HLA-DRB1*08-positive patients carrying two copies of 'short' alleles GA 13 and/or GA 16 compared to healthy controls (16% vs 6%; P n ¼ 4 ¼ 0.016). Our data indicate that the 'short' alleles of the SH2D2A promoter could contribute to the genetic susceptibility to JRA.
T-cell-specific adapter protein (TSAd) is an SH2 domain-containing intracellular adapter molecule that is expressed in thymocytes and activated mature T cells. 1 The exact role played by TSAd in T-cell signal transduction is unknown. TSAd may be involved in inhibiting early T-cell signaling events. 2 There are also indications that TSAd may be involved in transcriptional regulation in the cell nucleus. 3 Recently, it was reported that mice lacking the SH2D2A gene develop spontaneous systemic lupus-like autoimmune disease when they get older, probably due to a defect in activation-induced T-cell death. 4 The SH2D2A gene encoding TSAd contains a variable number (n ¼ 13-33) of GA repeats in its promoter region located at position À340 upstream of the first coding ATG. 5 Initial analysis of the SH2D2A promoter identified the minimal promoter to be located proximal to position À236 upstream of the first coding ATG, whereas a putative silencer element was identified in the region encompassed by position À500 to À310, thus including the GA repeat. 6 We previously showed that 'short' alleles of the GA repeat in the SH2D2A promoter conferred lower expression of TSAd in activated CD4 T cells compared to long alleles. Hence, individuals being homozygous for 'short' alleles of this GA repeat in the SH2D2A gene promoter display reduced expression of TSAd in activated T cells. 7 Moreover, there is an increased frequency of 'short' alleles (GA 13 and GA 16 ) among patients with multiple sclerosis (MS), suggesting that the SH2D2A gene may contribute to the genetic susceptibility to develop this disease. 7 This study was aimed to assess whether polymorphism of the SH2D2A gene promoter is also associated with juvenile rheumatoid arthritis (JRA). JRA is a chronic inflammation of joints that affects children. The pathogenesis is not known, but an antigen-driven autoimmune process is proposed, in which auto-reactive T cells play a central role in joint inflammation and destruction. 8, 9 Both susceptibility to and severity of this disease are largely genetically determined, 10, 11 and the genes responsible are mostly unknown. The only genetic factors that have been firmly shown to contribute to JRA are genes within the HLA complex. 12 Considering the putative major role of T cells in the pathogenesis of JRA, the T-cell regulatory SH2D2A gene is an a priori candidate susceptibility gene in JRA.
We analyzed the distribution of polymorphic GA alleles of the SH2D2A gene in 210 JRA patients and 558 healthy unrelated individuals as controls (shown in Figure 1 ). The frequency of the short GA 13 allele was significantly increased among JRA patients compared to the controls (0.098 vs 0.05; OR ¼ 1.8; P nc ¼ 0.0053; P n ¼ 8 ¼ 0.042; for correction numbers, see figure legends), whereas the frequency of the GA 16 allele did not differ among patients and controls. Since we previously observed that genotypes homozygous for the short GA 13 and GA 16 alleles or heterozygous GA 13 /GA 16 were associated to MS, we specifically examined these three genotypes in JRA patients. As can be seen from Figure 2 , all the three genotypes were increased among the JRA patients, but only the heterozygous GA [13] [14] [15] [16] genotype reached statistical significance (5% vs 1%; OR ¼ 3.9; 95% CI (1.4-11.6); P n ¼ 4 ¼ 0.036). Overall, JRA patients carried significantly more frequent two copies of 'short' alleles (GA 13 and/or GA 16 ) compared to healthy controls (10% vs 6%; OR ¼ 1.9; 95% CI (1.1-3.5); P n ¼ 2 ¼ 0.04). Intriguingly, a higher frequency of individuals homozygous for GA and/or heterozygous for GA [13] [14] [15] [16] was observed in patients carrying the DRB1*08 allele, the strongest risk factor in pauci-and poly-RF-negative JRA subgroups, 13 compared to those patients being negative for the DRB1*08 allele ( Figure 3) ; however, these differences did not reach statistical significance due to insufficient number of patients in each group. The SH2D2A gene is located on chromosome 1, and DRB1 is located on chromosome 6; thus alleles at these two loci are inherited independently of each other. We therefore also compared patients carrying the DRB1*08 allele with the total group of healthy controls, and observed significant differences in the frequency of individuals being heterozygous for GA [13] [14] [15] [16] (9% in patients vs 1% in controls; OR ¼ 7.6, 95% CI (2.2-26), P n ¼ 8 ¼ 0.008). When considering the three short genotypes as a group, a total of 16% in patients compared to 6% of the controls carried such genotypes; OR ¼ 3.2, 95% CI ¼ 1.4-6.9; P n ¼ 4 ¼ 0.016) (Figure 3 ). There were no significant differences in the genotype frequencies between controls and patients being negative for the DRB1*08 allele.
JRA comprises a heterogeneous group of rheumatic disorders that differ in severity, outcome and HLA association. To examine whether the observed SH2D2A allelic association is due to a specific subgroup of JRA we divided patients into subgroups that include: systemic JRA (n ¼ 20), polyarticular rheumatoid factor (RF)- has previously been reported. Methods: A SH2D2A gene segment containing the GA repeats was amplified by polymerase chain reaction (PCR) amplification as described previously. 7 The PCR products were separated on a 4.25% urea-polyacrylamide gel and identified according to size on an ABI 377XL DNA sequencer (PE Applied Biosystems, Foster City, CA, USA). The frequencies of alleles were compared by means of w 2 statistics or Fisher's exact test, when appropriate. The strength of association was estimated by odds ratios (OR) with 95% confidence interval (95% CI). P-values were corrected according to the Bonferroni method by multiplying with the number of comparisons performed. For comparisons of SH2D2A GA repeat alleles, this was the number of alleles with the frequency higher than 5% plus the remaining alleles lumped into one group (n ¼ 8). The significant association is shown with * (0.1 in patients vs 0.05 in controls; OR ¼ 1.8; 95% CI ¼ 1.2-2.7; P nc ¼ 0.0053; P n ¼ 8 ¼ 0.042). Figure 2 The genotypic frequencies of 'short' alleles in JRA patients and healthy controls. Genotypes of JRA patients (N ¼ 210) and healthy controls (N ¼ 558) were only compared in individuals having inherited at least one copy of the short allele (eg GA 13 and GA 16 ). Thus, the total number of genotypes considered was n ¼ 4, or n ¼ 2, when the short genotypes were lumped together into one group. GA13-13 (2/210 vs 1/558), GA13-16 (10/210 vs 7/558; OR ¼ 3.9; 95% CI ¼ 1.4-11.6; P Ã n¼4 ¼ 0.036), GA ( Figure 3 The genotypic frequencies of 'short' alleles in JRA patients stratified for the presence of DRB1*08 compared to healthy controls. The genotypic frequencies of 'short' alleles in patients with JRA positive for DRB1*08 (N ¼ 68) vs patients negative for DRB1*08 (N ¼ 142) or random healthy controls (N ¼ 558): GA 13-13 (2/68 vs 0/ 142 and 1/558, respectively), GA [13] [14] [15] [16] (6/68 vs 4/142 and 7/558, respectively), GA (3/68 vs 7/142 and 24/558, respectively), S-S (individuals carrying 'short' alleles GA 13 and/or GA 16 ) (11/68 vs 11/142, and 32/558, respectively). When patients were subgrouped according to HLA-DRB1*08 status, the total number of genotype comparisons performed was n ¼ 8, or when 'short' alleles were lumped n ¼ 4. *DR8-positive patients vs healthy controls; OR ¼ 7.6, 95% CI ¼ 2.2-26, P n ¼ 8 ¼ 0.008. **DR8-positive patients vs healthy controls; OR ¼ 3.2, 95% CI ¼ 1.4-6.9; P n ¼ 4 ¼ 0.016.
positive JRA (n ¼ 11), polyarticular RF-negative JRA (n ¼ 59) and pauciarticular JRA (n ¼ 120). An increased frequency of GA 13 was observed in all JRA subgroups (0.10 vs 0.05 in controls), however, only in patients with pauciarticular arthritis the GA 13 allele showed tendency to significant increase in frequency (OR ¼ 1.8; 95% CI ¼ 1.3-2.8; P nc ¼ 0.03), probably due to the higher number of investigated patients.
Our results suggest that the shortest allele (GA 13 ) of the SH2D2A gene promoter could contribute to the genetic susceptibility of JRA, similar to what we have observed in MS. 7 The associations of JRA and MS with less transcriptionally active short SH2D2A alleles support our notion that reduced expression of the immuneregulatory TSAd protein in activated T cells may increase the susceptibility to develop autoimmune diseases. The recent report that mice lacking the murine TSAd protein develop spontaneous autoimmune disease 4 lend support to this view. Interestingly, the SH2D2A gene is located within a congenic fragment on the murine chromosome 3, which influences genetic susceptibility to collageninduced arthritis, as well as the chronicity of experimental allergic encephalomyelitis (Sundvall et al, 14 Jirholt et al 15 and Martina Johannesson, personal communication).
The observed association of the short GA repeat to JRA could primarily be due to other polymorphisms in the SH2D2A gene region in linkage disequilibrium (LD) with the GA repeat alleles. We previously identified two single-nucleotide polymorphisms (SNPs) in the 1-kb fragment of the SH2D2A promoter upstream of the first ATG, which were only present on chromosomes carrying the GA 16 allele. 6 Three SNPs in intron 2 5 were found not to be in LD with the GA repeats examined in this study (Dai and Spurkland, unpublished results) . A number of other SNPs in the SH2D2A gene have now also been identified (http://www.ncbi.nlm.nih.gov/SNP/ snp_ref.cgi?locusId ¼ 9047). Whether these SNPs in the promoter or within the gene influence the expression level or function of the SH2D2A gene is at present unknown.
Taken together, the SH2D2A gene encoding TSAd may represent a novel susceptibility gene in JRA, and may possibly also represent a general susceptibility gene for autoimmune diseases. In polygenic diseases, such as juvenile arthritis and multiple sclerosis, several genes with only modest effect are thought to determine whether disease occurs. The observation that DRB1*08-positive patients display even higher frequency of the associated SH2D2A alleles strengthen the impression that SH2D2A polymorphism contributes to the genetic susceptibility in already genetically predisposed individuals. Additional studies in patients from different populations are thus necessary to confirm the association of SH2D2A gene to development of autoimmune disease.
